EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

A Phase 1 Drug‐Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK‐ Positive or ROS1 ‐Positive Solid Tumors

Michael J Hanley iD, Manolo D'Arcangelo, Enriqueta Felip, Pilar Garrido, Jiaxi Zhu, Meng Ye, Florin Vranceanu, Neeraj Gupta iD

The Journal of Clinical Pharmacology · 2023

DOI: 10.1002/jcph.2198 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift The Journal of Clinical Pharmacology, 2023. Verfasst von Michael J Hanley und 7 weiteren Autor:innen. Beteiligte Einrichtung: Takeda Development Center Americas, Inc., Lexington, Massachusetts, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Brigatinib is a next‐generation anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of patients with ALK ‐positive ( ALK +) non–small cell lung cancer (NSCLC). A phase 1 drug‐drug interaction study was conducted to evaluate the effect of multiple‐dose administration of brigatinib on the single‐dose pharmacokinetics of midazolam, a sensitive cytochrome P450 3A substrate. In cycle 1, patients with ALK + or ROS1 + solid tumors, including NSCLC, received a single 3‐mg dose of midazolam as an oral solution alone on day 1 and then coadministered with brigatinib on day 21 (brigatinib 90 mg once daily on days 2‐8; 180 mg once daily on days 9‐28). After cycle 1, patients could continue to receive brigatinib in 28‐day treatment cycles. The primary study objective was to characterize the effect of brigatinib 180 mg once daily on midazolam pharmacokinetics. The secondary objective was to assess safety. Exploratory efficacy endpoints included objective response rate and progression‐free survival. Brigatinib was generally well tolerated, and safety data were consistent with the known safety profile. Among the 10 patients with ALK + NSCLC, the confirmed objective response rate was 30% and median progression‐free survival was 7.2 months. Coadministration of brigatinib reduced midazolam maximum observed plasma concentration by ≈16% (geometric least‐squares mean ratio, 0.836 [90%CI, 0.662‐1.056]) and area under the plasma concentration–time curve from time 0 to infinity by ≈26% (geometric least‐squares mean ratio, 0.741 [90%CI, 0.600‐0.915]). Thus, brigatinib is a weak inducer of cytochrome P450 3A in vivo.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansCytochrome P-450 CYP3AProtein-Tyrosine KinasesMidazolamAnaplastic Lymphoma KinaseProto-Oncogene ProteinsProtein Kinase InhibitorsDrug InteractionsOrganophosphorus CompoundsPyrimidines

Stichwörter der Autor:innen

anaplastic lymphoma kinasebrigatinibcytochrome P450 (CYP) 3Adrug-drug interactionmidazolamnon-small cell lung cancerprotein kinase inhibitors

Substanzen

Cytochrome P-450 CYP3AProtein-Tyrosine KinasesMidazolamAnaplastic Lymphoma KinaseProto-Oncogene ProteinsProtein Kinase InhibitorsbrigatinibOrganophosphorus CompoundsPyrimidinesROS1 protein, human

Autor:innen und Institutionen

  • Takeda Development Center Americas, Inc., Lexington, Massachusetts, USA.
  • AUSL Romagna, Ravenna RA, Italy.
  • Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • IRYCIS, Ramón y Cajal University Hospital, Madrid, Spain.

ORCID-Profile: Michael J Hanley, Neeraj Gupta

Zitieren

APA

Hanley, M. J., D'Arcangelo, M., Felip, E., Garrido, P., Zhu, J., Ye, M., Vranceanu, F., & Gupta, N. (2023). A Phase 1 Drug‐Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK‐ Positive or ROS1 ‐Positive Solid Tumors. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.2198

Vancouver

Hanley MJ, D'Arcangelo M, Felip E, Garrido P, Zhu J, Ye M, et al. A Phase 1 Drug‐Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK‐ Positive or ROS1 ‐Positive Solid Tumors. The Journal of Clinical Pharmacology. 2023. doi:10.1002/jcph.2198

BibTeX
@article{Hanley2023,
  author = {Hanley, Michael J and D'Arcangelo, Manolo and Felip, Enriqueta and Garrido, Pilar and Zhu, Jiaxi and Ye, Meng and Vranceanu, Florin and Gupta, Neeraj},
  title = {A Phase 1 Drug‐Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK‐ Positive or ROS1 ‐Positive Solid Tumors},
  journal = {The Journal of Clinical Pharmacology},
  year = {2023},
  doi = {10.1002/jcph.2198}
}
Kostenlos starten →